# EDGAR Filing Document

**Accession Number:** 0001888014
**File Stem:** 0001213900-25-104758
**Filing Date:** 2025-10
**Character Count:** 2679
**Document Hash:** 3f72f4a351663ced5aaa4a5da0561b9e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-104758.hdr.sgml**: 20251031

**ACCESSION NUMBER**: 0001213900-25-104758

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251031

**FILED AS OF DATE**: 20251031

**DATE AS OF CHANGE**: 20251031

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AKANDA CORP.
- **CENTRAL INDEX KEY:** 0001888014
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41324
- **FILM NUMBER:** 251441434

**BUSINESS ADDRESS:**
- **STREET 1:** 1A, 1B LEAROYD ROAD
- **CITY:** NEW ROMNEY
- **STATE:** X0
- **ZIP:** TN28 8XU
- **BUSINESS PHONE:** 442034889514

**MAIL ADDRESS:**
- **STREET 1:** 77 KING STREET WEST, SUITE 400
- **STREET 2:** C/O DENTONS CANADA LLP
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 0A1

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **October 2025**

Commission File Number: **001-41324**

**AKANDA CORP.**

(*Name of registrant*)

**100 King Street W, Suite 1600**

**Toronto, Ontario M5X 1G5, Canada**

*(Address of principal executive office)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

On Thursday, October 30, 2025 at 10:00 a.m. (Toronto time), Akanda Corp. (the "**Company**") convened its previously announced special meeting (the "**Meeting**") of the holders of common shares of the Company. At the Meeting, at which a quorum was present, the Meeting was adjourned to November 28, 2025. Accordingly, the Meeting will be reconvened on Friday, November 28, 2025 at 10:00 a.m. (Toronto time) at the offices of Gowling WLG (Canada) LLP, Suite 1600, 100 King Street, West, Toronto, ON, M5X 1G5.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **AKANDA CORP.** | **AKANDA CORP.** | **AKANDA CORP.** |
|  | (Registrant) | (Registrant) | (Registrant) |
| Date: October 31, 2025 | By: | /s/ Katie Field | /s/ Katie Field |
|  |  | Name: | Katie Field |
|  |  | Title: | Interim Chief Executive Officer and Director |

---